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Abstract 
Aim: This study was designed to detect the association between factor V Leiden mutation and retinal vein 
occlusion.Methods: A total 60 adult newly diagnosed retinal vein occlusion patients ( branch or central types) 
with or without systemic disorders were included in this study in addition to 84apparently healthy adult control 
persons. Factor V Leiden mutation by PCR- RFLP technique was done for all cases of patients and controls 
groups.Results: The number of patients express FVL mutation was 13/60 (21%), while that of control subjects 
7/84 (8.3%)and the P- value reach to (0.023).The Odd ratio was 3.043 with a confidence interval of (1.133-
8.171)that indicate a strong association between FVL mutation and retinal vein occlusion. At the same time the 
etiologic fraction (EF) was 0.436which mean that FVL mutation remain as a risk factor not a cause for retinal 
vein occlusion.Conclusions:  FVL mutation is significantly higher in patients than control group, and consider a 
strong risk factor for retinal vein occlusion. 
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Introduction: 
A German pathologist, Rudolf Virchow at 1856, distinguish a variety of causes for thrombosis which include 
(stasis, injury to the vessels wall and abnormal blood consistency) and whose efforts lead to the maturity of 
thrombophilia as a concept[1]. 
Thrombophilia refers to predispositions to thromboembolism , in practice the term is used to describe 
patients who are at significantly increase long-term risk of venous and arterial thromboembolism. The 
predisposing factors may be genetically determined, acquired, or both[2]. AT 1994 a group  from Leiden city in 
Netherlands, recognized the most common mutation in factor V that made it to have a resistance to the action of 
activated protein C, this was called factor V Leiden[3]. 
APC is a potent inhibitor of the coagulation system. Its function is cleaving the activated forms of 
factors V and VIII[4]. Around 95% of APC resistance identified to caused by factor V Leiden mutation[5]. FVL 
is the most common known type of inherited thrombophilia, with a prevalence of 3% to 8% in Caucasian 
population,1.2% in African Americans and  infrequent in native African, Japanese and Chines populations[6]. 
The FVL mutation is a point mutation in the exon 10 of factor V gene in chromosome 1, single nucleotide 
substitution (guanine to adenine ) at nucleotide 1691 in factor V gene lead to an amino acid arginine substitute 
by glutamine at position 506 [7]. The effect of this is that more activated FV existing within the prothrombinase 
complex and more thrombin production that lead to hypercoagulable state (thrombophilia)[8]. 
Retinal vein occlusion is a common retinal vascular disease after diabetic retinopathy and it consider as 
multifactorial disease in its pathogenesis, many earlier studies established thrombophilia as a common patho- 
etiologic cause in retinal vein occlusion[9]. 
 
Patients, materials and methods:  
The present study is an observational case control study. A total 60 adult newly diagnosed retinal vein occlusion 
patients in addition to 84apparently healthy adult control persons was included in this study. All patients were 
collected from Al-Diwanyia Teaching Hospital/units of ophthalmology, the diagnosis of retinal vein 
occlusion(branch or central types) was made from specialist of ophthalmology by suggestive clinical history and 
Fundoscopic examination, all of them have normal (CBC, Blood film, and ESR Levels).The following tests were 
done for all including random blood, blood urea, serum cholesterol, thyroid stimulating hormone, antinuclear 
antibody, Kaolin clotting time, anti-cardiolipin antibodies IgG and IgM in  order to exclude the common 
acquired causes of thrombophilia. All patients and controls blood samples tested by PCR-RFLP in order to 
determine the presence of factor V Leiden mutation. 
Factor V Leiden analysis: genomic DNA was isolated from the EDTA blood samples by using ''Genomic DNA 
extraction kit'' for Whole Blood (Bioneer. Korea), this mutation was detected by using PCR-RFLP method [10]. 
Briefly, the region flanking the mutation was amplified by PCR(forward primer 
TCAGGCAGGAACAACACCAT, reverse primer GGTTACTTCAAGGACAAAATACCTGTAAAGCT)and 
the PCR products digested with the restriction enzyme HindIII. The products from the digestion were separated 
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on a 3% agarose gel, stained by ethidium bromide and visualized on a UV Transilluminator. 
Statistical analysis: Achieved by Chi-square test which used to study association between nominal variables. 
Odd ratio was used to calculate risk with 95% confidence interval, in addition to Student t-test. P-value was 
considered significant when it was less than  or equal to 0.05. 
Results: The proportion of patients with factor V Leiden mutation were significantly higher than that of control 
subjects, 21 % versus 8.33 % (P=0.023), as shown in table 1. the odd ratio was 3.043 with a confidence interval 
of (1.133 – 8.171). The etiologic fraction (EF) was 0.436. These results suggested a strong association between 
factor V Leiden mutation  and retinal vein occlusion. 
Table 1: Proportion of patients and control subjects expressing factor V Leiden mutation    
 
Patients Control 
  
95 % CI 
 
Factor V L No. % No. % P-value Odd ratio Lower Upper EF 
Yes 13 21.67 7 8.33 
     
No 47 78.33 77 91.67 0.023 3.043 1.133 8.171 0.436 
Total 60 100.00 84 100.00 
     
Mean age of patients with factor V Leiden mutation was not significantly different from that of patients without 
factor V Leiden mutation as shown in table 2. 
Table 2:Comparison of mean age between patients with factor V Leiden mutation and patients without 
Parameter 
Factor V L (Yes) Factor V L (No) 
 P-value 
Mean SE Mean SE 
Age 50.00 3.14 47.51 1.65 0.486 
No significant association was found between gender of patients and factor V mutation (P= 0.387), as shown in 
table 3. 
Table 3:Association between gender of patients and factor V Leiden mutation 
 
Male Female Total 
Factor VL No. % No. % No. % 
Yes 6 17.65 7 26.92 13 21.67 
No 28 82.35 19 73.08 47 78.33 
Total 34 100.00 26 100.00 60 100.00 
P= 0.387 
      
 
Discussion 
Several risk factors were contributed for development of retinal vein occlusion ocular or systemic, however the 
exact etiology remain unclear and thought to be multifactorial in nature. Several hemostatic factors have been 
implicated in the pathogenesis of retinal vein occlusion like reduced PC, PS, AT III levels, FVL and prothrombin 
genes mutation. 
In this study there is no significant statistical difference between the mean ages of patients group 
(48years) and control group (46 years) that usually related to the design of study regarding age and gender 
statistically matched studied groups.  The number of patients shown increment with increasing agers and is more 
frequency in age more than 50 years, this consist with some studies like study of Janssen MC et al.[11].        This 
increment may explain by association of systemic and environmental risk factors of thrombophilia in such age 
groups. In addition no significant statistical difference was found in male: female ratio between patient group 
and control group, like in study of S. Roger, R. L. Mcintosh, N. Cheung et al.[12],  that found RVO prevalence 
did not vary according to the gender , that may related to the absence of additional risk factors in female group 
like oral contraceptive pills, hormone replacement therapy, immunological disease and pregnancy association. 
FVL is the most common inherited thrombophilia known, with consequence inactivated 10-20 times 
more slowly than native form of factor V the result is increasing the generation of thrombin [13].  In our study 
the number of patients express FVL mutation was 13/60 (21%), while that of control subjects 7/84 (8.3%)and the 
P- value reach to (0.023). That mean the FVL mutation is significantly higher in patients than control group. Odd 
ratio was 3.043 with a confidence interval of (1.133-8.171), that indicate a strong association between FVL 
mutation and retinal vein occlusion. These findings were consist with the study of Greiner K, Peetz D, Winkgen 
A, et al.[14]. At the same time the etiologic fraction (EF) was 0.436,which mean that FVL mutation remain as a 
risk factor not a cause for RVO, and this result is highly consist with many other studies that showing FVL 
mutation is associated risk for RVO in addition to other important inherited or acquired factors [15, 16, 17]. 
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The mean age of patients with FVL (50 years) was statistically not significant difference from patients 
without such mutation (47.51 years), that FVL mutation can occur at any age group possibly alone or in 
association with other risk factors, these findings are consist with study of Rehak M, Rehak J, Muller M. et al. 
[17], while not consist with study of Arséne S, Delahousse B, Regina S, et al.[16] possibly related to small 
sample size of our study or  to the differences in the nature of mutation in different populations. Also no 
significant association was found between genders of patients with FVL mutation, that thrombogenic risk factors 
for female patients were excluded like OCCP, HRT, immunological disorders or pregnancy association and 
findings mostly related to the same risk in the male groups of acquired factors. 
In this study no significant statistical difference in the mean of most biochemical and immunological 
parameters in patient with FVL mutation and those without such mutation, that FVL mutation may play a sole 
role in pathogenesis of RVO separated from other acquired risk factors which already excluded in most of our 
patients. So the inherited causes of thrombosis play a major role in the pathogenesis and subsequently prevention 
of RVO even in the absence of associated acquired systemic factors. 
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